<DOC>
	<DOCNO>NCT02294461</DOCNO>
	<brief_summary>Purpose study ass effect enzalutamide time Prostate Specific Antigen ( PSA ) progression compare placebo chemotherapy na√Øve subject progressive metastatic prostate cancer fail androgen deprivation therapy</brief_summary>
	<brief_title>An Asian Study Evaluate Efficacy Safety Oral Enzalutamide Progressive Metastatic Prostate Cancer Patients</brief_title>
	<detailed_description>This study multinational Phase 3 , randomize , double-blind , placebo-controlled efficacy safety study oral enzalutamide ( formerly MDV3100 ) asymptomatic mildly symptomatic subject progressive metastatic prostate cancer disease progression despite androgen deprivation therapy . Subjects must previously treat cytotoxic chemotherapy . Approximately 30 Chinese subject allocate PK cohort . The subject PK cohort request hospitalized one day date randomization least completion assessment plan Day 3 . All subject PK cohort undergo blood sample PK analysis unchanged enzalutamide major metabolite regardless treatment arm .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell feature Ongoing androgen deprivation therapy GnRH analogue bilateral orchiectomy Progressive disease despite androgen deprivation therapy define rise PSA level progressive soft tissue bone disease No prior treatment cytotoxic chemotherapy Asymptomatic mildly symptomatic prostate cancer Severe concurrent disease , infection , comorbidity , judgment Investigator , would make patient inappropriate enrollment Known suspect brain metastasis active leptomeningeal disease History another malignancy within previous 5 year curatively treat nonmelanomatous skin cancer History seizure include febrile seizure condition may predispose seizure ( e.g. , prior stroke , brain arteriovenous malformation , head trauma loss consciousness require hospitalization ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Enzalutamide</keyword>
	<keyword>Androgen receptor</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Xtandi</keyword>
</DOC>